The University of Queensland School of Biomedical Sciences, Brisbane, Queensland 4072, Australia.
Biol Reprod. 2010 Apr;82(4):751-8. doi: 10.1095/biolreprod.109.076661. Epub 2009 Dec 23.
Maternal hyperglycemia is believed to be the metabolic derangement associated with both early pregnancy loss and congenital malformations in a diabetic pregnancy. Using an in vitro model of embryo exposure to hyperglycemia, this study questioned if increased flux through the hexosamine signaling pathway (HSP), which results in increased embryonic O-linked glycosylation (O-GlcNAcylation), underlies the glucotoxic effects of hyperglycemia during early embryogenesis. Mouse zygotes were randomly allocated to culture treatment groups that included no glucose (no flux through HSP), hyperglycemia (27 mM glucose, excess flux), 0.2 mM glucosamine (GlcN) in the absence of glucose (HSP flux alone), and O-GlcNAcylation levels monitored immunohistochemically. The impact of HSP manipulation on the first differentiation in development, blastocyst formation, was assessed, as were apoptosis and cell number in individual embryos. The enzymes regulating O-GlcNAcylation, and therefore hexosamine signaling, are the beta-linked-O-GlcNAc transferase (OGT) and an O-GlcNAc-selective beta-N-acetylglucosaminidase (O-GlcNAcase). Inhibition of these enzymes has a negative impact on blastocyst formation, demonstrating the importance of this signaling system to developmental potential. The ability of the OGT inhibitor benzyl-2-acetamido-2-deoxy-alpha-D-galactopyranoside (BADGP) to reverse the glucotoxic effects of hyperglycemia on these parameters was also sought. Excess HSP flux arising from a hyperglycemic environment or glucosamine supplementation reduced cell proliferation and blastocyst formation, confirming the criticality of this signaling pathway during early embryogenesis. Inhibition of OGT using BADGP blocked the negative impact of hyperglycemia on blastocyst formation, cell number, and apoptosis. Our results suggest that dysregulation of HSP and O-GlcNAcylation is the mechanism by which the embryotoxic effects of hyperglycemia are manifested during preimplantation development.
母体高血糖被认为与糖尿病妊娠中的早期妊娠丢失和先天畸形有关。本研究采用胚胎暴露于高血糖的体外模型,质疑增加己糖胺信号通路(HSP)的通量是否会导致胚胎 O-连接糖基化(O-GlcNAcylation)增加,从而为胚胎发生早期高血糖的糖毒性作用提供基础。将小鼠受精卵随机分配到无葡萄糖(HSP 通量为零)、高血糖(27mM 葡萄糖,过量通量)、无葡萄糖时的 0.2mM 氨基葡萄糖(GlcN)(仅 HSP 通量)的培养处理组,并通过免疫组化监测 O-GlcNAcylation 水平。评估 HSP 处理对胚胎第一分化(囊胚形成)的影响,以及个体胚胎中的凋亡和细胞数量。调节 O-GlcNAcylation 的酶,即β-连接-O-GlcNAc 转移酶(OGT)和 O-GlcNAc 选择性β-N-乙酰氨基葡萄糖苷酶(O-GlcNAcase),对 hexosamine 信号具有重要作用。这些酶的抑制作用对囊胚形成有负面影响,表明该信号系统对发育潜能的重要性。还寻求了 OGT 抑制剂苯甲酰基-2-乙酰氨基-2-脱氧-α-D-半乳糖吡喃糖苷(BADGP)逆转高血糖对这些参数的糖毒性作用的能力。高血糖环境或氨基葡萄糖补充引起的 HSP 通量增加会降低细胞增殖和囊胚形成,证实了该信号通路在胚胎发生早期的关键性。使用 BADGP 抑制 OGT 阻断了高血糖对囊胚形成、细胞数量和凋亡的负面影响。我们的结果表明,HSP 和 O-GlcNAcylation 的失调是高血糖在着床前发育过程中表现出胚胎毒性作用的机制。